International Congress on Targeted Anticancer Therapies 2012

Oncology Meeting Resources

08 Mar - 10 Mar, Amsterdam, Netherlands

From this page, you may download, if you are an ESMO member, a PDF version of presentations given at TAT 2012 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Search Meeting Resources by Keyword

Presenter Presentation title Session title
Elizabeth Eisenhauer 1 - NDDO Honorary Award Lecture 2012: Miles to go before we sleep: Fifteen years of targeted therapy development and the path ahead Opening Ceremony
Lee Ellis 2 - Keynote Lecture: Challenges in translating success from the lab to the clinic: A perspective on our current infrastructure and suggestions on ways to improve it Opening Ceremony
Josep Tabernero 3 - PI3K pathway inhibitors: How deep should we go? Phase I Studies, Completed or in Progress
Amita Patnaik 4 - The evolution of PI3 kinase inhibitors: Results of a first-in-human Phase I study of BAY 80-6946 in patients with advanced solid tumours Phase I Studies, Completed or in Progress
Antoine Hollebecque 5 - A phase 1 study of LY2584702, a p70S6 kinase inhibitor, with erlotinib or everolimus in patient with advanced solid tumours Phase I Studies, Completed or in Progress
Karim Benhadji 6 - A phase 1 dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of oral LY2584702 a p70S6 kinase inhibitor Phase I Studies, Completed or in Progress
Jean Charles Soria 7 - First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumours Phase I Studies, Completed or in Progress
Aled Edwards 9 - Genomics in drug discovery and development New Technologies and Models in Drug Discovery and Development
Alain Herrera 13 - NBTXR3 nanoparticles for radioenhancement: Rationale for the first- in-man study in advanced soft tissue sarcoma New Technologies and Models in Drug Discovery and Development
Marie-Catherine Vozenin 16 - New drugs on the horizon targeting stem cells in NSCLC Stem Cells and Cancer Stem Cells
Roger Griffin 17 - Educational introduction: DNA repair inhibitors; a medicinal chemist's perspective DNA Repair Beyond PARP
Shivani Kummar 18 - Development of markers of DNA repair DNA Repair Beyond PARP
Ruth Plummer 19 - Understanding failure of PARP inhibition in the clinic DNA Repair Beyond PARP
John Pollard 20 - Inhibition of the DNA damage response kinase, ATR, as a promising anti-cancer approach DNA Repair Beyond PARP
Yves Pommier 21 - PARP inhibition and efficacy of topoisomerase I inhibitors DNA Repair Beyond PARP